You are here

  • Home
  • Archive
  • Volume 82, Issue 7
  • Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang

Article info

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
Free

Authors

  • James Cheng-Chung Wei Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan PubMed articlesGoogle scholar articles
  • Tae-Hwan Kim Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Mitsumasa Kishimoto Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Naoki Ogusu Clinical Development Center, Kyowa Kirin Co, Ltd, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Haeyoun Jeong Development Department, Kyowa Kirin Korea Co, Ltd, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Shigeto Kobayashi Department of Internal Medicine and Rheumatology, Juntendo University Koshigaya Hospital, Saitama, Japan PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Shigeto Kobayashi, Juntendo University Koshigaya Hospital, Saitama 343-0032, Japan; shigeto{at}juntendo.ac.jp
View Full Text

Citation

Wei JC, Kim T, Kishimoto M, et al
Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
Annals of the Rheumatic Diseases 2023;82:e169.

Publication history

  • Received May 25, 2021
  • Accepted June 15, 2021
  • First published June 25, 2021.
Online issue publication 
June 12, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.